3D Cell Culture Industry Overview

The global 3D cell culture market size was estimated at USD 1.57 billion in 2023 and is expected to expand at a compound annual growth rate (CAGR) of 11.22% from 2024 to 2030.

The growth of the market can be attributed to the rising efforts to develop potential alternatives to animal-based testing and the availability of funding programs for research. Moreover, consistent efforts in RD activities by biopharmaceutical companies for drug development discovery, and emphasis on the adoption of 3D cell cultures in cancer research are other factors anticipated to fuel market growth over the projected period. Animal models are largely used in cellular-based studies for studying the outlook of various diseases. However, they carry several demerits such as a lack of response accuracy, differences in response from different species, etc. Thus, to manage these issues, various government organizations are involved in promoting alternative ways for drug development.

Gather more insights about the market drivers, restrains and growth of the 3D Cell Culture Market

The COVID-19 pandemic had a significant impact on the market. The COVID-19 pandemic has presented researchers with the opportunity to investigate the novel contagious virus for the creation of therapeutic and diagnostic tools. Numerous prominent pharmaceutical and biotechnology companies have been engaging in extensive RD efforts to produce innovative vaccines, therapies, and testing kits. As a result, there has been a substantial increase in the need for cell culture tools in research applications. Furthermore, the pandemic has increased the demand for new cell-based models, organoids, and high-throughput screening platforms for research drug discovery efforts. The urgency to combat the pandemic increased the demand for bioreactors and culture systems for applications in vaccine production and drug testing.

The rising burden of chronic diseases, and medical ailments such as multiple organ failure has created a robust demand for organ transplants. Whereas the dearth of donors has propelled the demand for alternative solutions, like regenerative medicine and tissue engineering. The 3D cell cultures system has an important role in nurturing organoids and functional tissue constructs for transplantation and drug analysis responses. Moreover, companies are launching products that would significantly boost the applications for tissue culture and tissue engineering. For instance, in June 2023, 3D BioFibR announced the launch of two novel 3D bioprinting collagen fiber products (CollaFibR 3D scaffold and μCollaFibR) for improved 3D cell culture.

Moreover, pharmaceutical companies, academic institutions, and research institutes are partnering to advance 3D cell culture technology. Such efforts accelerate technology advancement, knowledge sharing, and standardization of protocols, resulting in the larger adoption of 3D cell culture techniques. In addition, the supportive government legislation, and funding support from public and private organizations have accelerated the RD activities in the market. For instance, in March 2023, ZEISS Ventures invested in InSphero to promote 3D cell culture research. Similarly, in November 2023, HeartBeat.bio got an investment of USD 4.94 million (€4.5 million) for the development of a specific type of platform which is 3D human tissue-based drug discovery for heart diseases.

Furthermore, robust demand for in-vitro testing models from a range of end users, and several organic and inorganic initiatives undertaken by market players is anticipated to facilitate market expansion in coming years. For instance, in December 2023, Charles River Laboratories announced their agreement with CELLphenomics, which is anticipated to expand their 3D in vitro services that would be used for drug screening purposes for cancer therapy. Similarly, in October 2020 Merck collaborated with D1 Med to accelerate manufacturing of D1Med’s 3-dimensional cells culture technology applications adopted in the drug development process.

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global recombinant DNA technology market size was valued at USD 728.9 billion in 2023 and is projected to grow at a CAGR of 5.4% from 2024 to 2030.
• The global DNA diagnostics market size was estimated at USD 10.64 billion in 2023 and is projected to grow at a CAGR of 4.51% from 2024 to 2030.

Key 3D Cell Culture Company Insights

Prominent players operating in the market are undertaking strategic activities such as new product launches, partnerships for product development, and investment activities to fuel market growth in the coming years.

Key 3D Cell Culture Companies:

The following are the leading companies in the 3D cell culture market. These companies collectively hold the largest market share and dictate industry trends. Financials, strategy maps products of these 3D cell culture companies are analyzed to map the supply network.

• Thermo Fisher Scientific, Inc.
• Merck KGaA
• PromoCell GmbH
• Lonza
• Corning Incorporated
• Avantor, Inc.
• Tecan Trading AG
• REPROCELL Inc.
• CN Bio Innovations Ltd
• Lena Biosciences

Recent Developments

In September 2023, Curi bio announced the launch of two platforms, that is, Nautilus and Stringray. These platforms are anticipated to assist researchers with their 2D or 3D cell culture interrogation on electrophysiology.

In July 2023, REPROCELL Inc. entered into a partnership with Vernal Biosciences to deliver mRNA services at scale for clinical and research applications in Japan. This strategy is aligned with REPROCELL’s aim to introduce cutting-edge preclinical clinical research solutions to the market.

In July 2023, 3D BioFibR, a Canada-based company, received an investment of nearly USD 3.52 million to expand the facility and launch collagen fiber products used for 3D bioprinting.

In June 2023, Lonza entered into a strategic business collaboration with Vertex Pharmaceuticals Incorporated, with an aim to support the production of Vertex’s range of fully differentiated insulin-producing, investigational stem cell-derived islet cell therapies for individuals with Type 1 diabetes and to speed up the clinical trials.

In February 2023, Corning Life Sciences announced its plans to unveil its advanced 3D culture tools and a new Elplasia plate featuring an open-well format for easing spheroid and organoid manipulations.

In February 2023, CN Bio announced the commercial product launch of the PhysioMimix - a single-organ higher throughput system. The system is developed to allow the earlier adoption of predictive models of liver Organ-on-a-Chip for humans in drug discovery workflows. By deploying 3D cell culture systems including PhysioMimix, researchers can more efficiently simulate the behavior of organs tissues, leading to more relevant and reliable preclinical research results.

In January 2023, CD BioSciences launched scaffold-based technology to help scientists achieve organotypic co-culture and simulate layered tissue structures.

Order a free sample PDF of the 3D Cell Culture Market Intelligence Study, published by Grand View Research.